Company History
Founded in 2019, Grit Bio is an R&D-driven, late-stage biopharmaceutical company developing next-generation immunotherapies for patients with cancer and autoimmune diseases worldwide.
Company established
Completed Series Seed financing
Completed Series A financing
Completed Series A+ financing
Developed GMP manufacturing capabilities for TIL products
Launched pilot manufacturing facility
Completed Series Pre-B and Series B financings
Completed Series B+ financing
Established GritBio Medicine in the United States
Shanghai Grit Bio and Suzhou Grit Bio recognized as High and New Technology Enterprises
Completed Series C financing
Beijing State-Owned Capital and Operation and Management Co., Ltd invested in Grit Bio; Grit Bio relocated to Beijing
Converted into a joint stock limited company
Subsidiary Vivacta completed Series Angel financing
Shanghai Grit Bio recognized as a Specialized, Sophisticated, Distinctive and Innovative SME
Actively advancing capital market initiatives overseas
Began building the R&D team
Established CMC process for GT101
Initiated an investigator-initiated trial (FIH) of GT101
Initiated the Phase I clinical trial of GT101 in China
Initiated a FlH trial of GT201
Completed patient enrollment in the Phase I clinical trial of GT101 in China
Obtained NMPA IND approval for GT201
Initiated FlH trials for the GT300 series
Initiated the pivotal Phase II clinical trial of GT101
Obtained GT201 IND clearance from US FDA
Obtained GT307 IND clearance from US FDA
Initiated a FlH of GT719
Initiated a FlH of GT801
Established NewCo subsidiary Vivacta
Initiated and accelerated development of LNP-based in vivo CAR-T programs
Established a joint venture with Junshi Biosciences to develop GT719
Obtained IND approval for GT101 in combination with toripalimab as first-line treatment for HNSCC
Obtained IND approval for GT201 in combination with toripalimab for HNSCC
Obtained NMPA IND approval for GT307